PharmaBlock Sciences (Nanjing), Inc.
Shenzhen Stock ExchangeTotal Valuation
PharmaBlock Sciences (Nanjing), Inc. carries a market capitalization of 7.54B, placing it among publicly traded companies globally. Its enterprise value stands at 8.35B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 7.54B |
| Enterprise Value | 8.35B |
Share Statistics
PharmaBlock Sciences (Nanjing), Inc. currently has 199.73M shares outstanding.
| Shares Outstanding | 199.73M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
PharmaBlock Sciences (Nanjing), Inc. trades at a trailing price-to-earnings ratio of 39.80. The price-to-sales ratio is 4.13, and the price-to-book ratio stands at 4.49.
| PE Ratio | 39.80 |
| PS Ratio | 4.13 |
| PB Ratio | 4.49 |
| P/TBV Ratio | 2.43 |
| P/FCF Ratio | 63.72 |
| P/OCF Ratio | N/A |
Enterprise Valuation
On an enterprise value basis, PharmaBlock Sciences (Nanjing), Inc. trades at an EV/EBITDA multiple of 26.78 and an EV/FCF ratio of 49.12. The EV/Sales ratio of 4.48 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 26.78 provides insight into valuation relative to core operating earnings.
| EV / Sales | 4.48 |
| EV / EBITDA | 26.78 |
| EV / EBIT | 26.78 |
| EV / FCF | 49.12 |
Financial Position
PharmaBlock Sciences (Nanjing), Inc. maintains a current ratio of 3.95, meaning it holds 4.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 38.13, indicating elevated leverage, while an interest coverage ratio of 5.46 demonstrates adequate ability to service its debt obligations.
| Current Ratio | 3.95 |
| Quick Ratio | 1.07 |
| Debt / Equity | 38.13 |
| Debt / EBITDA | 4.43 |
| Interest Coverage | 5.46 |
Financial Efficiency
PharmaBlock Sciences (Nanjing), Inc. posts a return on equity of 11.76 and a return on invested capital of 5.79.
| Return on Equity (ROE) | 11.76 |
| Return on Assets (ROA) | 3.77 |
| Return on Invested Capital (ROIC) | 5.79 |
| Return on Capital Employed (ROCE) | 8.01 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 1.60 |
Taxes
Over the trailing twelve months, PharmaBlock Sciences (Nanjing), Inc. has paid 31.09M in income taxes, reflecting an effective tax rate of 13.85.
| Income Tax | 31.09M |
| Effective Tax Rate | 13.85 |
Stock Price Statistics
PharmaBlock Sciences (Nanjing), Inc.'s stock has declined approximately -0.42541877% over the past 52 weeks. The 50-day moving average sits at 36.34, while the 200-day moving average is 38.80.
| Beta (5Y) | N/A |
| 52-Week Price Change | -0.42541877% |
| 50-Day Moving Average | 36.34 |
| 200-Day Moving Average | 38.80 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, PharmaBlock Sciences (Nanjing), Inc. generated 1.86B in revenue and converted that into 193.35M in net income, yielding earnings per share of 0.97. EBITDA reached 311.82M, while operating income came in at 311.82M.
| Revenue | 1.86B |
| Gross Profit | 623.69M |
| Operating Income | 311.82M |
| Pretax Income | 224.44M |
| Net Income | 193.35M |
| EBITDA | 311.82M |
| EBIT | 311.82M |
| Earnings Per Share (EPS) | 0.97 |
Balance Sheet
PharmaBlock Sciences (Nanjing), Inc. holds 728.54M in cash and equivalents against 1.38B in total debt, resulting in a net debt position of 1.04B. Total book value stands at 1.71B, with working capital of 2.02B providing operational flexibility.
| Cash & Cash Equivalents | 728.54M |
| Total Debt | 1.38B |
| Net Debt | 1.04B |
| Equity (Book Value) | 1.71B |
| Book Value Per Share | 8.62 |
| Working Capital | 2.02B |
Cash Flow
After subtracting -120.77M in capital expenditures, free cash flow totaled -120.77M - equivalent to -0.61 per share.
| Operating Cash Flow | N/A |
| Capital Expenditures | -120.77M |
| Free Cash Flow | -120.77M |
| FCF Per Share | -0.61 |
Margins
PharmaBlock Sciences (Nanjing), Inc. operates with a gross margin of 33.47, reflecting its pricing power and cost economics. The operating margin of 16.73 and net profit margin of 10.38 provide insight into operational efficiency.
| Gross Margin | 33.47 |
| Operating Margin | 16.73 |
| Pretax Margin | 12.04 |
| Profit Margin | 10.38 |
| EBITDA Margin | 16.73 |
Dividends & Yields
The company's payout ratio of 37.90 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | 0.37 |
| Dividend Yield | N/A |
| Payout Ratio | 37.90 |
| Shareholder Yield | 1.49 |
| FCF Yield | 1.57 |
Stock Splits
PharmaBlock Sciences (Nanjing), Inc.'s most recent stock split took place on April 26, 2021 with a 10:13 split ratio.
| Last Split Date | 4/26/2021 |
| Split Ratio | 10:13 |
Scores
PharmaBlock Sciences (Nanjing), Inc. posts an Altman Z-Score of 3.90, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 3.90 |